Catégorie : Biotech

STROMACARE

by jbertholdin Biotech, Pharma

STROMACARE

About the company


StromaCare is a biotech company specialized in discovering and developing new cancer treatments through their understanding of stromal tissue biology. They develop innovative oncology drugs, both as standalone treatments and in combination with other therapies, for treating solid tumors based on the novel approach of modulating stromal components. How cancer develops and progresses is linked to the tumor stroma. The stroma limits the efficiency of immune cells against tumor cells, facilitates the migration of tumor cells, and prevents the access of treatments to the tumor.

At StromaCare, they aim to make the stroma ‘permeable’ to immune cells and other molecules of interest to eliminate the tumor.

About the solution

StromaCare identified a set of stromal players and characterized their roles. Their lead drug candidate, STRO-501, a monoclonal antibody, targets a key stromal player called βig-h3, which is common to most cancers and serves as a novel T-cell regulator. This lead monoclonal antibody has demonstrated strong efficacy in preclinical studies, shows a favorable safety profile, and has received a favorable opinion from the EMA. StromaCare aims to start their clinical trial in 18 to 24 months, either as a standalone treatment or in combination with anti-PD1 in resistant cancers.

Their pipeline includes other targets and antibodies addressing different aspects of stromal biology.

Website
Key information

–  Therapeutic areas: Oncology, Immune diseases

–  Based in: Lyon (FRANCE)

–  Employees: 11 – 50

– Created in: 2022

NG BIOTECH

by jbertholdin Biotech

NG BIOTECH

About the company


They make rapid diagnostics that improve healthcare outcomes within antimicrobial resistance, infectious disease, liver function, and women’s health. They offer solutions for professional use and for home testing (OTC).

NG Biotech commercializes worldwide in more than 70 countries. Their Product Portfolio includes a range of rapid tests for antimicrobial resistance (carbapenems, ESBL, Colistin, Vancomycin, Acinetobacter), infectious disease (C. Auris, Covid, Nipah, Yersinia Pestis, Lassa, Burkholderia), liver function, women’s health, and OTC.

About the solution

Their solution :

– Antimicrobial Resistance tests : Rapid detection and characterization of carbapenemases and ESBL from bacteria colony and from direct sample such as urine.

– Women Health test : 1st Home Blood Pregnancy test

Website
Key information

–  Therapeutic areas: Antimicrobial Resistance, Infectious Disease, Women’s Health

–  Based in: Guipry (FRANCE)

–  Employees: 11 – 50

– Created in: 2012

H.A.C PHARMA

by jbertholdin Biotech, Pharma

H.A.C PHARMA

About the company

H.A.C. Pharma is a European pharmaceutical company incorporated in 2007 in France. H.A.C. Pharma markets and promotes high therapeutic value drugs, especially in pathologies with reduced alternatives for the patient.

The company works with a network of trusted distributors in 6 European countries (Spain, Italy, Belgium, Austria, Switzerland and Portugal) and directly in France with its own sales force.

The company’s drugs are mainly promoted to specialists in hospital setup in the area of endocrinology, neuropsychiatry, gynecology, onco-hematology and gastroenterology.

About the solution

H.A.C. Pharma is your partner of choice to launch your medicines in Europe: from clinical assessment of medical needs through go-to-market strategy, early-access program and full registration, importation and distribution, to promotion to specialists.

Website
Key information

–  Therapeutic areas: Neurology and CNS, Endocrinology, Hemato-oncology, Autoimmune diseases, Cardiology, Gynecology

–  Based in: Caen (FRANCE)

–  Employees: 11 – 50

– Created in: 2007

CONTACT
Philippe BissayCEO

philippe.bissay@hacpharma.com

IKTOS

by jbertholdin Biotech, Digital Health, Pharma

IKTOS

About the company

Incorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design.

Iktos is developing a proprietary and innovative solution based on deep generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project.

The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

About the solution

Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

Iktos offers the possiblity to its partners to use it unique technology via proprietary SaaS software platforms: Makya for de novo generative design and Spaya for retrosynthesis and synthetic access. Its partners can also rely on Iktos expertise to run integrated drug discovery projects from hit discovery, hit-to-lead, lead optimization, all the way down to preclinical drug candidate.

Website
Key information

–  Therapeutic areas: Any therapeutic areas including oncology, CNS / neurology, Immunology, Infectious diseases, Rare diseases

–  Based in: Headquarters and lab: Paris (FRANCE)
Additional offices: US and JAPAN

–  Employees: 51 – 200

– Created in: 2016

CONTACT
Bose AvirupChief Business Officer

avirup.bose@iktos.com

EXELIOM BIOSCIENCES

by jbertholdin Biotech, Pharma

EXELIOM BIOSCIENCES

About the company

Exeliom Biosciences is a clinical-stage immunotherapy company developing EXL01, a NOD2-targeting, single-strain live biotherapeutic designed to enhance the efficacy of checkpoint inhibitors by reprogramming macrophages.

EXL01 is currently being evaluated in six Phase II trials, including four active oncology studies in gastric cancer, NSCLC, HCC, and RCC in combination with PD-1 or PD-L1 inhibitors. Key clinical readouts are expected over the next 18 to 24 months, including an interim analysis in 1L gastric cancer (n=120) in mid-2026. To date, EXL01 has shown promising target engagement results in patients.

About the solution

EXL01 is a first-in-class, macrophage-targeted immunomodulator that enhances the efficacy of checkpoint inhibitors by activating the NOD2 pathway through a highly specific mechanism.

Its activity is driven by the peptidoglycan structure on the bacterial membrane, which acts as a hyperagonist of NOD2, leading to macrophage reprogramming in a context-dependent manner. What sets EXL01 apart is the way this peptidoglycan is delivered: not as a synthetic compound, but as part of a live, commensal strain that transports it directly to the lower intestine, where it interacts with immune cells. This approach combines the precision of a small molecule with the targeted delivery and safety of a native microbiome agent.

Website
Key information

–  Therapeutic areas: Immuno-Oncology, Inflammatory Bowel Diseases, Infectious Diseases

–  Based in: Paris (France)

–  Employees: 1 – 10

– Created in: 2016

AQEMIA

by jbertholdin Biotech, Pharma

AQEMIA

About the company

AQEMIA is a next-gen pharmatech company generating one of the world’s fastest-growing drug discovery pipeline. Their mission is to design fast innovative drug candidates for dozens of critical diseases.

About the solution

Their differentiation lies in their unique quantum and statistical mechanics algorithms fueling a generative artificial intelligence to design novel drug candidates, with already several drug discovery successes in internal pipeline as well as in collaboration with Pharma companies.

Website
Key information

–  Therapeutic areas: Oncology, Immunology, Inflammation, Central Nervous System, Metabolism

–  Based in: Paris (FRANCE)

–  Employees: 51 – 200

– Created in: 2019